MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

38.61 2.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

38.35

Max

38.67

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	11.593 87.826
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+15.74% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	429M 2.1B
Ankstesnė atidarymo kaina	36.58
Ankstesnė uždarymo kaina	38.61

Naujienos nuotaikos

By Acuity

34%

66%

110 / 370 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-09 22:18; UTC

Rinkos pokalbiai

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-09 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-01-09 21:43; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

2026-01-09 20:39; UTC

Rinkos pokalbiai

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

2026-01-09 20:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

2026-01-09 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

2026-01-09 20:30; UTC

Rinkos pokalbiai

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

2026-01-09 20:15; UTC

Rinkos pokalbiai

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

2026-01-09 20:07; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-09 20:07; UTC

Rinkos pokalbiai

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

2026-01-09 19:58; UTC

Įsigijimai, susijungimai, perėmimai

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

2026-01-09 19:42; UTC

Rinkos pokalbiai

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

2026-01-09 19:38; UTC

Įsigijimai, susijungimai, perėmimai

Wolters Kluwer Acquires StandardFusion >WTKWY

2026-01-09 19:31; UTC

Uždarbis

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

2026-01-09 19:28; UTC

Uždarbis

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

2026-01-09 18:30; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

2026-01-09 18:23; UTC

Rinkos pokalbiai

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

2026-01-09 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-09 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-09 17:19; UTC

Rinkos pokalbiai

Energy Prices Not Seen Supporting More Drilling -- Market Talk

2026-01-09 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-01-09 17:07; UTC

Rinkos pokalbiai

McDonald's Promotions Appear Successful -- Market Talk

2026-01-09 17:06; UTC

Rinkos pokalbiai

Oil Futures on Track for Weekly Gains -- Market Talk

2026-01-09 17:05; UTC

Uždarbis

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

2026-01-09 16:57; UTC

Rinkos pokalbiai

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

2026-01-09 16:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-09 16:46; UTC

Rinkos pokalbiai

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

15.74% į viršų

12 mėnesių prognozė

Vidutinis 43.83 USD 15.74%

Aukščiausias 55 USD

Žemiausias 32 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

110 / 370 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.